

SENSEI BIOTHERAPEUTICS, INC.

CHARTER OF THE SCIENCE AND TECHNOLOGY COMMITTEE

PURPOSE AND POLICY

The purpose of the Science and Technology Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Sensei Biotherapeutics, Inc. (the “*Company*”) is to assist the Board in fulfilling the Board’s responsibilities in overseeing the Company’s technologies and its research and development activities, strategy, and goals and to advise the Board with respect to the Committee’s view on such matters.

The objectives of the Committee shall be as follows:

- To advise the Board regarding endorsement to current and planned research and development programs, validating timelines, budget and key milestones;
- To monitor and advise the Board about the progress on the approved research and development activities;
- To advise the Board regarding the scientific merit of pipeline programs and technologies for licensing and acquisition opportunities;
- To provide advice regarding emerging science, therapeutic trends and foreseeable opportunities; and
- To provide advice to the Company’s scientific team on aspects of the Company’s research and development, preclinical and clinical programs.

COMPOSITION

The Committee shall consist of at least two members of the Board. At least one member of the Committee shall be an independent director as determined by the Board, in accordance with the applicable independence requirements of The Nasdaq Stock Market (“*Nasdaq*”), when and as required by Nasdaq. Each member of the Committee shall have sufficient scientific and/or medical expertise to review and evaluate appropriately the Company’s preclinical and clinical programs and research and development programs. The members of the Committee shall be appointed by and serve at the discretion of the Board. Resignation or removal of a Committee member from the Board for any reason shall automatically constitute resignation or removal, as applicable, from the Committee. Vacancies occurring on the Committee shall be filled by the Board. The Committee’s chairperson shall be designated by the Board or, if it does not do so, the Committee members shall elect a chairperson by vote of a majority of the full Committee. The Chair (or in his or her absence, a member designated by the Chair) shall preside at all meetings of the Committee.

MEETINGS AND MINUTES

The Committee shall hold such regular or special meetings as its members deem necessary or appropriate. The presence in person or by telephone/virtual conference of a majority of the Committee’s members shall constitute a quorum for any meeting of the Committee. All actions of the Committee will require (i) the vote of a majority of the members present at a meeting of the

Committee at which a quorum is present, or (ii) a unanimous written consent of the members of the Committee then serving. Other members of the Board who are not members of the Committee, specific members of management and external advisers may be invited to attend all or part of any meeting, as and when appropriate. Minutes of each meeting will be kept and all such minutes and actions by unanimous written consent will be distributed to each member of the Committee, members of the Board who are not members of the Committee and the Secretary of the Company. The Chair of the Committee shall report to the Board from time to time or whenever so requested by the Board.

AUTHORITY

The Committee shall have authority to retain and determine compensation for, at the expense of the Company, external scientific or other advisors or consultants as it deems necessary or appropriate in the performance of its duties; provided that any such compensation shall comply with applicable laws and regulations. The Committee shall also have authority to pay, at the expense of the Company, ordinary administrative expenses that, as determined by the Committee, are necessary or appropriate in carrying out its duties. Expenditures for external resources that are expected to be material or outside the ordinary course of the Committee's practices shall be recommended by the Committee for the approval of the Board.

Each member of the Committee shall have full access to all books, records, facilities and personnel of the Company as deemed necessary or appropriate by any member of the Committee to discharge his or her responsibilities hereunder. The Committee shall have authority to require that any of the Company's personnel, counsel or any other consultant or advisor to the Company attend any meeting of the Committee or meet with any member of the Committee or any of its special outside legal, accounting or other advisors or consultants. The operation of the Committee shall be subject to the Bylaws of the Company as in effect from time to time and Section 141 of the Delaware General Corporation Law. The approval of this charter by the Board shall be construed as a delegation of authority to the Committee with respect to the responsibilities set forth herein.

RESPONSIBILITIES

To implement the Committee's purpose and policies, the Committee shall be charged with the following duties and responsibilities, with the understanding, however, that the Committee may supplement and, except as otherwise required by applicable law, deviate from these activities as appropriate under the circumstances:

1. The Committee shall review, evaluate and report to the Board regarding strategy, plans and goals, as well as progress and performance, of the Company's preclinical and clinical programs and research and development activities.

2. The Committee shall from time to time meet with the Company's research and development team to evaluate the plans, goals and performance of the Company's preclinical and clinical programs and research and development projects, and make recommendations to the Board as appropriate in the opinion of the Committee to fulfill the goals of such preclinical and clinical

programs and research and development projects, including the infrastructure and resources made available by the Company for such programs.

3. The Committee shall identify and discuss significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its preclinical and clinical programs and research and development activities.

4. The Committee shall review and advise the Board regarding the scientific, medical, research and development, and intellectual property aspects of any proposed transactions such as investments, acquisitions and licenses;

5. In conjunction with the Board and the Audit Committee of the Board, the Committee shall assist with oversight of the proper and timely disclosure made by the Company's management regarding any significant developments, issues or problems with ongoing preclinical studies, clinical trials, tests, or other studies or analyses.

6. The Committee shall, not less frequently than annually, evaluate the performance of the Committee, including a review of the Committee's compliance with this Charter, and review and reassess this Charter and submit any recommended changes to the Board for its consideration and approval.

7. The Committee shall perform such other functions, duties and responsibilities and have such other powers as may be necessary or appropriate as may be assigned to the Committee, from time to time, by the Board.

Adopted April 4, 2022